InMed-logo-01
Subscribe
NASDAQ_Logo

Press Releases

Press Releases

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
InMed Provides Update on Management Changes
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
Displaying 1 - 10 of 224
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Manufacturing

Investor

Corporate

Learn

© Copyright 2022 InMed Pharmaceuticals Inc.